Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Solubilization of fluasterone.

L Zhao1, P Li, S H Yalkowsky

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, USA.

Journal of Pharmaceutical Sciences
|October 9, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Class I PI3K in oncogenic cellular transformation.

Oncogene·2008
Same author

Evidence for association of D1S249 locus on human chromosome 1 with the susceptibility to essential hypertension in Han Chinese.

Science in China. Series C, Life sciences·2008
Same author

Retrieval of the physiological state of human skin from UV-Vis reflectance spectra - a feasibility study.

Journal of photochemistry and photobiology. B, Biology·2008
Same author

Caffeic acid phenethyl ester prevents cerebellar granule neurons (CGNs) against glutamate-induced neurotoxicity.

Neuroscience·2008
Same author

Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis.

The Journal of international medical research·2008
Same author

Effects of neonatal oxytocin treatment on aggression and neural activities in mandarin voles.

Physiology & behavior·2008
Same journal

Immune tolerance platforms to mitigate unwanted immune responses.

Journal of pharmaceutical sciences·2026
Same journal

Green, renewable, or low-carbon? A framework for informed solvent selection in pharmaceutical sciences.

Journal of pharmaceutical sciences·2026
Same journal

Theranostic potential of ramucirumab functionalized magnetoliposomes for targeted delivery of sorafenib and MRI.

Journal of pharmaceutical sciences·2026
Same journal

Intranasal mucoadhesive chitosan microspheres of ranolazine: Formulation, design, and pharmacokinetic evaluation.

Journal of pharmaceutical sciences·2026
Same journal

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
Same journal

A mathematical framework for predicting tablet weight variability from blend particle size distribution and tooling geometry.

Journal of pharmaceutical sciences·2026
See all related articles

Solubilizing nonpolar drugs like Fluasterone is key for parenteral formulations. Modified beta-cyclodextrins, specifically sulfobutyl ether-beta-cyclodextrin and hydroxypropyl-beta-cyclodextrin, significantly enhanced Fluasterone solubility.

Area of Science:

  • Pharmaceutical Science
  • Drug Delivery
  • Formulation Development

Background:

  • Solubilizing nonpolar drugs is critical for parenteral formulations.
  • Fluasterone, a nonpolar drug, presents challenges in achieving adequate solubility for intravenous administration.

Purpose of the Study:

  • To investigate and assess solubility enhancement techniques for Fluasterone.
  • To compare the efficacy of cosolvency, micellization, and complexation methods.
  • To identify the most effective solubilizing agents for Fluasterone.

Main Methods:

  • Evaluated cosolvency, micellization, and complexation strategies.
  • Utilized modified beta-cyclodextrins, including sulfobutyl ether-beta-cyclodextrin (SBEbetaCD) and hydroxypropyl-beta-cyclodextrin (HPbetaCD).

Related Experiment Videos

  • Quantified Fluasterone solubility in aqueous solutions and with different excipients.

    • Main Results:

    • The intrinsic solubility of Fluasterone in water was determined to be 1.55 x 10(-4) mM.
    • Solubility increased to 3.13 mM in 20% SBEbetaCD.
    • Solubility further increased to 4.04 mM in 20% HPbetaCD.

    Conclusions:

    • Modified beta-cyclodextrins are highly effective in enhancing Fluasterone solubility.
    • HPbetaCD demonstrated superior solubilization capacity for Fluasterone compared to SBEbetaCD.
    • These findings support the use of cyclodextrin complexation for parenteral formulation of poorly soluble drugs like Fluasterone.